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Abstract
The germinal center (GC) is the anatomical site where humoral immunity evolves. B cells undergo 
cycles of proliferation and selection to produce high-affinity Abs against Ag. Direct linkage of a 
TLR9 agonist (CpG) to a T-dependent Ag increases the number of GC B cells. We used a T-
dependent Ag complexed with CpG and a genetic model for ablating the TLR9 signaling adaptor 
molecule MyD88 specifically in B cells (B-MyD88− mice) together with transcriptomics to 
determine how this innate pathway positively regulates the GC. GC B cells from complex Ag-
immunized B-MyD88− mice were defective in inducing gene expression signatures downstream of 
c-Myc and mTORC1. In agreement with the latter gene signature, ribosomal protein S6 
phosphorylation was increased in GC B cells from wild-type mice compared with B-MyD88− 
mice. However, GC B cell expression of a c-Myc protein reporter was enhanced by CpG attached 
to Ag in both wild-type and B-MyD88− mice, indicating a B cell–extrinsic effect on c-Myc protein 
expression combined with a B cell–intrinsic enhancement of gene expression downstream of c-
Myc. Both mTORC1 activity and c-Myc are directly induced by T cell help, indicating that TLR9 
signaling in GC B cells either enhances their access to T cell help or directly influences these 
pathways to further enhance the effect of T cell help. Taken together, these findings indicate that 
TLR9 signaling in the GC could provide a surrogate prosurvival stimulus, “TLR help,” thus 
lowering the threshold for selection and increasing the magnitude of the GC response. 
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TLRs recognize pathogen-associated molecular patterns and serve as key mediators of the 
innate immune response against pathogens. However, TLRs are expressed on both adaptive 
and innate immune cells. Deficiency in these receptors or their key signaling molecules, 
such as MyD88, impairs both innate and adaptive responses to pathogens (1–3). The dual 
function of TLRs in initiating the early inflammatory response while at the same time 
directly shaping the slower Ag-specific adaptive response shows that these receptors act 
through multiple elements within the immune system. It has been appreciated for a number 
of years that several TLRs are expressed by B cells, and these receptors regulate B cell 
activation and fate decisions (4, 5). Studies using mice in which the critical TLR signaling 
component MyD88 is selectively ablated in B cells or mixed bone marrow chimeras in 
which B cells were selectively deficient in a particular TLR revealed that such mice also 
have substantial defects in germinal center (GC) and plasma cell generation and in isotype-
switched Ab titers in response to multiple TLR agonists mixed with T-dependent and T-
independent Ags (6–8).
This biological role for TLR signaling in B cells is important for making high-quality Abs to 
a number of viral infections of mice, in which case endosomal TLR7 and TLR9, which 
recognize nucleic acids, are critical (6, 9). BCR-mediated endocytosis of the Ag and 
associated BCR signaling delivers TLR ligands to the endosomal location of these receptors 
(10, 11). In addition, TLR7 and TLR9 function in B cells is required for the production of 
anti-DNA and antiribonucleoprotein autoantibodies in several mouse models of systemic 
lupus erythematosus (12).
One experimental strategy for studying how BCR signaling and TLR9 signaling enhance the 
GC response is to immunize with a T-dependent Ag physically coupled to a synthetic TLR9 
agonist, CpG deoxyoligonucleotide (oligo) (13). To activate the potential of TLR9 to 
enhance a GC response, the Ag must be oligovalent (as is the case for a haptenated protein) 
(13). The TLR9 ligand can be present in virus-like particles (VLPs) (7, 14) or combined 
with DOTAP adjuvants (15) to form liposome-like oligovalent Ags. MyD88 deficiency in B 
cells compromises GC B cell numbers and Ab titers to such Ags (7, 13), but how TLR 
signaling enhances the response that remains dependent upon T follicular helper (Tfh) cells 
is unclear. In a murine model of autoimmune lupus in which TLR7 and TLR9 are necessary 
for sustained autoreactive B cell responses, cognate autoreactive T cells could partially 
rescue GC B cell activation defects in the absence of TLR7/9 (16). This suggests the overlap 
of prosurvival signals derived from T cell help and TLR7/9 signaling in supporting GC B 
cell survival and humoral immunity, but the molecular nature of the signals provided by 
TLRs was not defined.
In this study, we explored the mechanistic basis by which a TLR9 ligand attached to an Ag 
signals within the Ag-specific B cell to promote the GC response. The wild-type (WT) GC B 
cells immunized with 4-hydroxy-3-nitro-phenylacetyl (NP)–haptenated T-dependent Ag 
complexed with a CpG oligo had increased oxidative phosphorylation, mTORC1, and c-Myc 
gene expression signatures compared with MyD88-deficient GC B cells. Remarkably, both 
c-Myc and mTORC1 are induced by Tfh cell–mediated interactions with GC B cells through 
CD40L:CD40 signaling (17–19). As such, MyD88-dependent TLR9 signaling induced gene 
expression signatures that were previously associated with Tfh cell help, suggesting that 
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TLR signaling in GC B cells enhanced the GC response by mimicking the effects of Tfh on 
the B cells, without replacing the requirement for Tfh. Together, these findings indicate that 
TLR9 signaling in GC B cells can provide a supplemental stimulus that allows more B cells 
to occupy the GC in an environment where Tfh cell help is limiting for survival.
MATERIALS AND METHODS
Generation of complex Ags and BCR stimulants
NP–chicken γ globulin (CGG) complex Ag was generated similarly to what has been 
previously published, with the following modi-fications:NP(14–30)CGG(Biosearch) was 
biotinylated using biotin(xx)-NHSS in DMF, as previously reported (13). The biotinylated 
NP(14–30)CGG was mixed (5 mg/ml) with streptavidin (Thermo Fisher Scientific) (10 
mg/ml) and 5’ biotinylated CpG oligo 1826 (5’-CCATGACGTTCCTGACGTT-3’) (IDT) or 
a 5’ biotinylated non-CpGoligo(5’-TCCAGGACTTCTCTCAGGTT-3’)(IDT)(5mg/ml) at a 
molar ratio of 1:4:48, respectively, in PBS for 24 h before being washed in 5 ml of PBS in an 
Amicon Ultra-15 Centrifugal Filter Unit 10 kD (Millipore) three times and resuspended at 
100 μg of total mass per 50 μl. Similarly, biotinylated anti-IgM (goat polyclonal; Jackson 
ImmunoResearch) was mixed with streptavidin and 5’ biotinylated CpG oligo 1826 (IDT) or 
a 5’ biotinylated non-CpG oligo (5 mg/ml) at a molar ratio of 2:1:2 in PBS for 24 h before 
being transferred to an Amicon Ultra-15 Centrifugal Filter Unit 10 kD filter (Millipore), 
washed three times with PBS, and resuspended at 1.5 μg anti-IgM per microliter.
Mice and immunizations
Mice used in these experiments consisted of Mb1-cre [C(Cg)-Cd79atm1(cre)Reth/EhobJ], 
MyD88flox[B6.129P2(SJL)-MyD88tm1Defr/J], c-Myc-GFP reporter (B6;129-Myctm1Slek/J) 
(backcrossed 10 timestoB6/J), and Em-Bcl2transgenic[C.Cg-Tg(BCL2)22Wehi/J] (a gift 
from the Cyster laboratory), all of which were maintained in house, according to all 
Institutional Animal Care and Use Committee guidelines.
Mice were immunized s.c. in the scruff and flanks with a total of 100 μg of NP-CGG in 
complex Ag for cell sorting and in vivo phospho-flow experiments and with 25 μg of NP-
CGG complex Ag in the footpad for c-Myc-GFP and general flow cytometry experiments. 
Draining lymph nodes were analyzed. Em-BCL2 transgenic c-Myc-GFP mice were 
immunized with 100 μg of NP (14–30)-CGG (Biosearch) in Alum Imject (Thermo Fisher 
Scientific)i.p., and GC B cells were isolated from spleen 12–14 d later.
RNA isolation and mRNA sequencing
Ten thousand NP+ GC B cells were collected by FACS sorting directly into the lysis buffer 
of the Dynabead direct mRNA extraction kit (Thermo Fisher Scientific). mRNA was isolated 
by use of poly-dT beads, according to the manufacturer’s instructions (Thermo Fisher 
Scientific). Library preparation and RNA sequencing (RNA-seq) was performed through the 
University of California, San Francisco Functional Genomics Core, aligned to the Ensembl 
mouse GRCh38.78 (mm10) genome using STAR software, and analyzed using DESeq2, as 
previously reported (20).
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Flow cytometry
Single-cell suspensions were prepared from draining lymph nodes or spleen by gently 
passing them through 70-μm nylon mesh filters. Cells were collected by centrifugation and 
incubated with anti-CD16/CD32 (2.4G2) in FACS buffer (PBS + 2% FBS + 2 μm EDTA 
+ 0.01% NaN3) to block Ab binding to Fc receptors before staining with Abs for surface 
markers. For phospho-flow analysis of in vivo cells, mice were perfused with 10% 
paraformaldehyde directly after sacrifice (Sigma-Aldrich), and single-cell suspensions from 
lymph nodes were prepared directly in 2% paraformaldehyde and incubated for 15 min on 
ice before permeabilizing the cell plasma membranes with ice-cold methanol. Fixed cells 
were rehydrated with PBS, washed by centrifugation in FACS buffer, and blocked and 
stained with Abs, as described above. Conjugated Abs used included PE-Cy7 anti-CD95 
(Jo2), FITC and PerCP-Cy5.5 anti-GL7, BV605 anti-CD19 (6D5), FITC anti-B220 (RA3–
6B2), biotin anti-CD11c, biotin anti-CD3e (145–2C11), biotin anti-Ter119, biotinanti-Gr1, 
ef450 anti-IgD (11–26c), biotin anti-CXCR4(2B11), APC anti-CD86 (GL-1), APC anti-
CD83 (Michel-19), AF647 anti-pS6(ser240/244) (D68F8), AF647 anti-pS6(ser235/236) 
(D57.2.2E), and AF647 anti-pAkt ser473 (D9E). Biotin conjugates were detected using 
BV711 or BV786 streptavidin (BioLegend). NP (8–30)-PE (Biosearch) was used to detect 
NP-binding B cells. Dead cells were detected using efluor780 or UV blue fixable viability 
dyes (Thermo Fisher Scientific). Flow cytometry analysis and sorting were performed on 
LSR II and FACSAria II cytometers (BD Biosciences), respectively.
In vitro and ex vivo naive and GC B cell isolation and stimulation
WT, Mb1-cre+ MyD88fl/fl (B-MyD88−), WT-c-Myc-GFP, and Mb1-cre+ MyD88fl/flMyc-
GFP+/+(B-MYD88− c-Myc-GFP)naive B cells were isolated using Dynabead negative CD43 
selection kit (Thermo Fisher Scientific) and stimulated in RPMI 1640 supplemented with 
10% FCS, HEPES, 2-ME, and L-glutamine with anti–IgM-CpG and anti–IgM-Non for 24 h, 
then stained for viability before being analyzed by flow cytometry or fixed before staining 
for phospho-flow. Eμ-BCL2 Myc-GFP B cells were isolated by anti-CD11c, anti-CD43, and 
anti-IgD (GC) or anti-GL7 (naive) biotin Abs, followed by an antibiotin magnetic bead 
isolation (Miltenyi), according to a previously published protocol (21). Purity was confirmed 
at least 95% B220+ for naive B cells and 90% Fas+, CD382 for GC B cells. Cells were 
stimulated with 10–20 μg of anti-CD40 (FGK4.51; Miltenyi), 10–20 μg of anti-IgM (goat 
polyclonal μ chain; Jackson ImmunoResearch), 75 nM CpG 1826 oligo (IDT), or 
combinations of these reagents for 4 h in complete RPMI 1640 medium and processed for 
flow cytometry.
Software and statistics
Data visualization and statistical calculations were performed using Prism (GraphPad). 
Statistical tests and p values for each experiment are specified in figure legends. For a single 
comparison between two groups, a Student t test was used; for multiple comparisons 
between preselected groups, a one-way ANOVA test with Holm–Sidak correction for 
multiple comparisons was used; and for multiple comparisons in which all groups were 
compared, a one way ANOVA test with a Tukey correction for multiple comparisons was 
used. Flow cytometry data were analyzed with FlowJo.
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Gene Set Enrichment Analysis (GSEA) was run on the graphical user interface according to 
the manufacturer’s recommendations (https://software.broadinstitute.org/gsea/doc/
GSEAUserGuideFrame. html) to compare the WT and MyD88− RNA-seq data sets using all 
genes (22).
RNA-seq data are publicly available on the Gene Expression Omnibus under accession 
number GSE126849 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126849.
RESULTS
TLR9 agonist complexed to T-dependent Ag increases the frequency and number of GC B 
cells in responseto immunization
Previous studies have demonstrated that attachment of a TLR7 or TLR9 ligand to an Ag can 
boost the GC Ab response (7, 13). We created two complex Ags composed of biotinylated 
NP-CGG complexed with streptavidin and either biotinylated CpG oligo or biotinylated 
control oligo yielding NP-CGG-CpG or NP-CGG-Non, respectively (13). C57BL/6 mice 
were immunized s.c. with either NP-CGG-CpG or NP-CGG-Non, and the GC response was 
analyzed at day 14 (D14) (Supplemental Fig. 1A). As the high-affinity anti-NP Ab response 
to NP-CGG is known to have a substantial contribution of λ L chain–containing Abs, we 
also analyzed the frequency of NP-binding, λ+ GC B cells. Mice immunized with NP-CGG-
CpG showed a 3.5-fold increase in the number of total GC B cells (CD19+, IgDlo, Fas+) as 
well as a 4-fold increase in the number of NP-binding λ+ GCB cells (Supplemental Fig.1B, 
1C). These results agree with a previous study using a similar complex Ag (13).
To specifically test the role of TLR9 agonism in the B cell compartment, we immunized B 
cell lineage-specific MyD88-deficient (B-MyD88−) and control Mb1-cre+ MyD88fl/+ or 
Mb1-cre+ MyD88+/+ (WT) mice with NP-CGG-CpG Ag and analyzed the GC response at 
D14 (Supplemental Fig. 1D, 1E). WT mice exhibited a 2.4-fold higher frequency and 
number of GL7hi GC B cells as compared with the B-MYD88− mice (Fig. 1A). Thus, in 
agreement with previous work, these results show that B cell TLR9 signaling enhances the 
GC response to a haptenated Ag attached to a TLR9 ligand. There was also likely to be some 
contribution of TLR signaling in another cell type, such as classical dendritic cells.
NP-CGG-CpG Ag induces MyD88-dependent c-Myc and mTORC1 signature gene 
expression
To determine the effect of TLR9 signaling on the GC response at a transcriptional level, we 
performed mRNA sequencing on NP-binding WT and B-MYD88− GC B cells at D14 
postimmunization with NP-CGG-CpG, using the gating strategy illustrated in Supplemental 
Fig. 1E. This analysis uncovered 479 differentially expressed genes (false discovery rate 
[FDR] < 0.05 by Fisher exact test), of which 260 were increased in WT and 219 were 
increased in B-MYD88− cells. Among the genes with higher expression in WT GC B cells, 
many corresponded to ribosomal proteins, NADH dehydrogenase, ATP synthase, and 
cytochrome oxidase machinery, pointing toward increased oxidative phosphorylation activity 
(Fig. 1B). This metabolic phenotype is consistent with the recent finding that TLR9 
signaling can rescue naive B cells from apoptosis resulting from mitochondrial dysfunction 
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elicited by BCR engagement in the absence of CD40 or TLR signals (23). There was also 
increased Ighg2c gene expression in WT samples compared with B-MYD88− samples as 
well as increased expression of Aicda, the gene encoding the activation-induced cytidine 
deaminase that is directly involved in somatic hypermutation and in class-switch 
recombination (Table I). These results are consistent with the strong effect of the TLR9 
ligand in promoting class switch to IgG2a/IgG2c (8, 13). Surprisingly, expression of the 
transcriptional regulator Bcl6, which directs the GC fate in B cells, was increased in B-
MYD88− GC B cells (Table I). Conversely, mRNA encoding the survival factor Bcl2 was 
higher in WT cells (Table I), suggesting that increased survival may contribute to the 
increased GC B cell frequency and number in the context of intact TLR9/MyD88 signaling.
To gain greater insight from the mRNA expression data sets, we applied GSEA to the 
hallmark gene sets (22). Gene sets enriched in WT compared with B-MYD88− GC B cells 
included the Myc signature with a normalized enrichment score (NES) = 2.38 and FDR < 
10−5, the E2F signature with an NES = 1.60 and FDR = 0.02, and the mTORC1 signature 
with an NES = 1.46 and FDR = 0.057 (Fig. 3B, Table II). We performed a leading-edge 
analysis on the hallmark subsets from Table II and found that the genes driving the 
difference in the context of mTORC1 and c-Myc had very little overlap, and thus these two 
gene signatures represented independent enrichments (Supplemental Fig. 2). Similarly, 
independently curated mTORC1 (24) and c-Myc (25) gene sets were also enriched in WT 
compared with B-MYD88− GC B cells (Fig. 1D, 1E, Table II). Furthermore, the KEGG 
ribosomal pathway showed a large enrichment in WT GC B cells (Table II). From our RNA-
seq, Aicda was increased 2-fold in WT compared with B-MYD88− cells (FDR = 0.088), 
concordant with this being positively regulated by mTORC1 signaling (26, 27). In contrast, 
no hallmark gene sets were enriched in the Ag-specific B-MYD88− GC B cells compared 
with the Ag-specific WT GC B cells (FDR q values.0.25, data not shown). Interestingly, 
both c-Myc and mTORC1 have been implicated as downstream effectors of Tfh cell help 
and their dysregulation negatively impacts the GC response (17–19). These results suggest 
that TLR9-MyD88 signaling in the Ag-specific GC B cell increases the transcriptional 
outputs of the c-Myc and mTORC1 pathways, either via direct transcriptional effects or 
indirectly by enhancing the ability of the GC B cells to interact with Tfh cells and receive 
CD40L and cytokine signals, which are known to promote these two programs.
TLR9 signaling in naive B cells increases c-Myc expression
To better understand how TLR9 signaling enhances the c-Myc pathway transcriptional 
response, we examined the effect of BCR signaling and TLR9 signaling on c-Myc protein 
expression. First, naive polyclonal B cells were stimulated through the BCR and TLR9 in a 
linked fashion by the addition of anti-IgM bound to streptavidin and biotin-conjugated CpG 
or biotinylated control oligos to make the complex artificial Ags anti–IgM-CpG and anti–
IgM-Non, respectively (28). To measure the c-Myc protein expression on a single-cell level, 
we crossed a knock-in c-Myc-GFP protein fusion reporter (29) to WT and B-MYD88− 
mouse strains. We stimulated purified naive B-MYD88− Myc-GFP or WT Mb1-cre+, 
MyD88+/+ c-Myc-GFP+/+ (WT-Myc-GFP) splenic B cells with either anti–IgM-CpG or 
anti–IgM-Non for 24 h and then analyzed the cells for c-Myc-GFP expression by flow 
cytometry (Fig. 2A). The presence of a TLR9 ligand attached to the anti-IgM Abs greatly 
Wigton et al. Page 6
Immunohorizons. Author manuscript; available in PMC 2019 September 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
enhanced c-Myc expression in naive B cells after 24 h, at which time, 90% of WT-Myc-GFP 
cells stimulated with anti–IgM-CpG were c-Myc-GFP+ (Fig. 2B). In contrast, WT-Myc-GFP 
cells stimulated with anti–IgM-Non and B-MyD88−Myc-GFP cells stimulated with either 
anti–IgMCpG or anti–IgM-Non exhibited much lower c-Myc induction at this time, with 5–
10% c-Myc-GFP+ cells (Fig. 2B). Less than 2% of unstimulated naive B cells of either 
genotype were c-Myc-GFP+. Per cell, c-Myc-GFP abundance was also increased by TLR9/
MyD88 signaling, with anti–IgM-CpG–stimulated WT-Myc-GFP B cells displaying a 4-fold 
increase in GFP mean fluorescence intensity (MFI) compared with anti–IgM-Non–
stimulated WT-Myc-GFP and B-MyD88−Myc-GFP cells under either stimulation condition 
(Fig. 2B). Thus, in naive B cells, combined Ag receptor and TLR9 signals induced c-Myc 
levels much more strongly than Ag receptor signals alone.
Attachment of a TLR9 ligand to the Ag increased the frequency of GC B cells expressing c-
Myc protein in a non–cell-intrinsic manner
We next used the c-Myc-GFP reporter to address the mechanism by which attachment of a 
TLR ligand to CGG increased the c-Myc transcriptional signature in GC B cells. Previous 
work established that CD40L delivered by Tfh cells strongly induces c-Myc expression in 
light zone (LZ) GC B cells, which consequently return to the dark zone (DZ) and undergo 
further clonal expansion (17, 18). Therefore, we examined c-Myc-GFP expression in D14 
LZ and DZ phenotype GC B cells, identified by elevated CD86/CD83 or CXCR4 
expression, respectively, from c-Myc-GFP+/+ mice immunized with NP-CGG-CpG or NP-
CGG-Non Ag (Fig. 2C, Supplemental Fig. 3A) (30, 31). Both immunization groups had 
similar distributions of DZ and LZ phenotype cells among GC B cells (NP-CGG-CpG: DZ = 
51 ± 6%, LZ = 41 ± 5%; NP-CGG-Non: DZ = 52 ± 10%, LZ = 44 ± 9%) (Supplemental Fig. 
3A). In agreement with our sequencing data, the NP-CGG-CpG Ag group had a higher 
percentage (2.7% versus 1.1%) and a greater mean number (3000 versus 1700) of c-Myc-
GFP+ GC B cells than NP-CGG-Non–immunized animals (Fig. 2D). A majority of c-Myc-
GFP+ cells exhibited an LZ phenotype for both immunization conditions (NP-CGG-CpG: 66 
± 9%; NP-CGG-Non: 69.8 ± 13%)(Supplemental Fig. 3B), consistent with previous studies 
showing enrichment of the LZ phenotype(31) and localization of c-Myc+ GC B cells to the 
LZ (17, 18).
To test whether TLR9/MyD88 signaling in the GC B cells contributed to the increased 
frequency of c-Myc–expressing GC B cells seen upon immunization with NP-CGG-CpG, 
we immunized WT-Myc-GFP and B-MyD88−Myc-GFP mice with either one allele or two 
alleles of the c-Myc-GFP fusion reporter and analyzed c-Myc-GFP expression at D14. 
Interestingly, neither the number nor percentage of c-Myc-GFP+ GC B cells was increased 
in the GC B cells from WT-Myc-GFP mice compared with the GC B cells from the B-
MyD88− Myc-GFP mice (Fig. 2E). The distribution of LZ and DZ phenotypes of bulk and 
c-Myc-GFP+ GC B cells were also unaltered by the inability of the B cells to signal via 
MyD88 (Supplemental Fig. 3C). The per cell c-Myc-GFP MFI was also similar in WT-Myc-
GFP and B-MyD88−Myc-GFP groups (Supplemental Fig. 3D). Thus, there was a non–B 
cell–intrinsic effect of attaching a TLR9 ligand to NP-CGG on expression of c-Myc-GFP. 
Moreover, these results suggest that the increased c-Myc transcription signature resulting 
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from TLR9/MyD88 signaling in GC B cells (Fig. 1) may have resulted from a regulatory 
change in c-Myc transcriptional activity, rather than an increase in c-Myc protein expression.
Dual TLR9 and BCR signaling increases phosphorylation of ribosomal protein S6 in naive 
B cells and in GC B cells
Next, we examined whether TLR9/MyD88 signaling in purified naive splenic B cells leads 
to enhanced Akt/mTOR signaling. Initially, purified naive splenic B cells were stimulated in 
vitro with anti-IgM complex Ags as before, and phosphorylation of mTORC1 targets was 
assessed by intracellular staining of permeabilized cells with phospho-specific Abs and flow 
cytometry. Remarkably, phosphorylation of ribosomal protein S6 on residues 235, 236, 240 
and 244, known mTORC1 targets detected by Abs specific for phosphorylated residues 235 
and 236 [pS6(ser235/236)] or for residues 240 and 244 [pS6(ser240/244)], was almost 
entirely dependent on CpG stimulation in naive B cells (Fig. 3A, Supplemental Fig. 4A). 
Anti–IgM-CpG–stimulated WT cells were 90% positive for pS6(ser240/244) at 24 h 
compared with the 5–15% range seen for WT B cells stimulated with anti–IgM-Non or for 
B-MyD88− B cells treated with either stimulus (Fig. 3B). The anti–IgM-CpG–stimulated 
WT B cells showed the highest pS6(ser240/44) MFI, which was 14 times greater than any 
other group (Fig. 3B). Cell size is in part dependent upon protein content of the cell, and WT 
B cells stimulated with anti–IgM-CpG also showed the largest increase in cell size forward 
light scatter compared with the three other groups (Fig. 3B), which is consistent with a role 
of mTORC1 in enhancing global protein synthesis.
Next, we examined the effect of including a TLR9 ligand attached to NP-CGG on the size of 
GC B cells and on their pS6 phosphorylation status. GC B cells were substantially larger 
than naive B cells, as would be expected, but no differences in cell size were evident when 
comparing B-MyD88− and WT GC at D14 postimmunization with NP-CGG-CpG Ag (Fig. 
3C). Additionally, no difference in cell size was evident when only NP-binding GC B cells 
of these two genotypes were compared (Fig. 3C). Using phospho-flow cytometry, we 
analyzed pS6(ser240/244) and pS6(ser235/236) in GC B cells. There was an increase in 
pS6(ser240/244) MFI of WT compared with B-MyD88− GC B cells that was significant (p = 
0.021) (Fig. 3D). However, we found that WT and B-MyD88− GC B cells exhibited similar 
MFI staining for pS6(ser235/236) (Supplemental Fig. 4B). When mice were immunized 
with NP-CGG-CpG versus NP-CGG-Non, we found a 2-fold increase in both 
pS6(ser240/244) (Fig. 3E) and pS6(ser235/236) in GC B cells (Supplemental Fig. 4C). 
Interestingly we saw an increase in the pS6 level of non-GC B cells in the NP-CGG-CpG–
immunized mice compared with NP-CGG-Non, indicating that another CpG responsive cell 
type alters the metabolic and inflammatory environment of the lymph node, increasing 
mTORC1 activity in non-GC B cells in a non–cell-intrinsic manner. Thus, combined CpG-
induced TLR signaling and BCR signaling positively regulated mTORC1 signaling robustly 
in naive B cells, and although all GC B cells had evidence of active mTORC1 signaling, 
consistent with previous studies (19, 32, 33), TLR9/MyD88 signaling appeared to further 
increase phosphorylation of the mTORC1 target pS6 by both B cell–intrinsic and –extrinsic 
mechanisms.
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Ex vivo stimulation of GC B cells with CpG oligo increases mTORC1 phosphorylation 
targets and c-Myc induction similarly to CD40 stimulation
To test whether TLR signaling ex vivo in GCB cells would enhance mTORC1 signaling and 
c-Myc expression in the absence of continued Tfh cell interaction, GC B cells were isolated 
from immunized Em-BCL2 transgenic mice (to promote their survival during in vitro 
culture) and stimulated with anti-CD40, anti-IgM, anti-IgM + CpG oligo, or anti-CD40 + 
anti-IgM for 4 h and fixed before staining for pS6(ser240/244). It was previously reported 
that both anti-IgM and anti-CD40 signaling are necessary to increase mTORC1 activity and 
induce c-Myc expression in GC B cells, whereas naive B cells respond to either stimulus 
individually(34). Similarly, we found that stimulation of naive B cells with anti-IgM and/or 
anti-CD40 for 4 h led to at least 90% of cells being pS6(ser240/244) positive (Fig. 4A, 4B). 
Furthermore, CpG stimulation led to 75% of naive cells being pS6(ser240/244) positive, and 
the addition of anti-IgM increased the response to >95% pS6(ser240/244) positive (Fig. 4A, 
4B). In contrast, ex vivo stimulation of Em-BCL2 transgenic GC B cells with anti-IgM alone 
failed to induce increased phosphorylation of this residue compared with unstimulated GC B 
cells (Fig. 4A, 4B). Either anti-CD40 or CpG oligo stimulation conditions increased the 
percentage of pS6(ser240/244)-positive Em-BCL2 GC B cells to comparable levels (50–
60%) (Fig. 4A, 4B). These results demonstrate that TLR9 stimulation and CD40 
engagement can have similar effects on mTORC1 signaling in GC B cells. Furthermore, 
stimulation of the BCR via anti-IgM did not increase the response to anti-CD40 or CpG 
oligo in the Em-BCL2 GC B cells.
Next, we crossed the c-Myc-GFP+/+ mice to the Eμ-BCL2 transgenic mice to facilitate 
examination of c-Myc expression in naive and GC B cells stimulated ex vivo. Naive c-Myc-
GFP+/WT B cells and c-Myc-GFP+/WT Eμ-BCL2 GC B cells were stimulated with anti-IgM, 
anti-CD40, or CpG oligos or combinations thereof. All stimulation conditions increased the 
expression of c-Myc-GFP substantially in the naive B cells (MFI increased 2.4-fold by anti-
IgM, 2.0-fold by anti-CD40, 1.7-fold by CpG, 3.7-fold by anti-IgM + anti-CD40, and 3.8-
fold by anti-IgM + CpG, compared with no stimulation), which is congruent with previous 
studies demon-stratingthat CpG induces c-Myc expression in immature and naive B 
cells(35,36). Thus, c-Myc induction in naive cells was responsive to each stimulus 
individually and exhibited an additive response to multiple stimuli. For the Em-BCL2 GC B 
cells, ex vivo anti-IgM stimulation did not induce c-Myc expression above the unstimulated 
control (1.1-fold increase in MFI) (Fig. 4C, 4D), similar to what was seen with 
phosphorylation sites on ribosomal protein S6. Incontrast, stimulation with CpG oligo 
oranti-CD40induced small but significant increases in c-Myc-GFP expression (MFI 
increased by 1.3-fold, p = 0.0007 and 1.2-fold, p = 0.0013, respectively, compared with no 
stimulation).Addition of anti-IgM may have further increased c-Myc-GFP expression, but it 
was not statistically significant compared with the individual stimulations. Thus, we did not 
see a clear synergy between anti-IgM and anti-CD40 stimulation for the induction of c-Myc 
expression or mTORC1 signaling, in contrast to a previous report (34). As both c-Myc 
expression and phosphorylation of a key mTORC1 target were increased to similar levels 
upon stimulation of GC B cells with anti-CD40 or CpG oligo, it is possible that TLR9 
signaling in GC B cells could be a partial surrogate for CD40-mediated Tfh cell help. 
According to this interpretation, more GC B cells would get prosurvival mTORC1 signaling 
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and c-Myc induction in the context of TLR9 signaling in the GC, lowering the need for 
CD40 stimulation and Tfh cell help. This would increase the number of cells that survive 
and the pool of GC B cells as a percentage of the B cell population.
DISCUSSION
Previous work established that a TLR ligand attached to a haptenated protein Ag or 
contained within a virus particle can promote the magnitude and quality of the GC reaction 
and, moreover, that TLR signaling within the Ag-specific B cell is an important contributor 
to that enhancement (7, 13). In this study, we used mRNA sequencing and GSEA to identify 
the intracellular transcriptional programs that were enhanced by coupled Ag and TLR9/
MyD88 signaling in GC B cells. Especially enhanced were the transcriptional signatures 
associated with c-Myc transcriptional activity and mTORC1 signaling. Both of these 
pathways are central to the control of cell growth and proliferation in many cell types and 
are critical in B cells for the GC response (17, 32, 33). Interestingly, Tfh cells recognizing 
Ag presented by GC B cells also stimulate these pathways in the Ag-presenting GC B cell, 
leading to positive selection of the GC B cells (18, 19, 37). Thus, one potential mechanism 
by which TLR9/MyD88 signaling may have enhanced c-Myc transcription and mTORC1 
signaling is by enhancing interactions of GC B cells with Tfh cells. Alternatively, TLR9/
MyD88 signaling in the Ag-specific B cells may have directly increased the transcriptional 
activities of one or both of these pathways. Consistent with the latter, direct mechanism, we 
found that ex vivo stimulation of Bcl2-transgenic GC B cells with a TLR9 ligand increased 
expression of a c-Myc-GFP protein reporter and increased phosphorylation of the mTORC1 
target protein ribosomal protein S6, in both cases, similarly to the response induced by anti-
CD40, which mimics a key aspect of helper T cell action.
It is likely that several mechanisms contributed to the enhanced c-Myc transcriptional 
activity seen in Ag-specific GC B cells responding to NP-CGG-CpG immunization. Both 
naive B cells and Bcl2-transgenic GC B cells cultured ex vivo and stimulated with a TLR9 
ligand oligo exhibited increased c-Myc-GFP protein reporter induction, indicating direct 
TLR9/MyD88 signaling can induce elevated levels of c-Myc protein. Moreover, MyD88 
signaling has been shown to stabilize c-Myc protein in intestinal epithelial cells (38). 
However, the increase in c-Myc-GFP expression in vivo after immunization with the NP-
CGG-CpG conjugate was seen not only in WT mice but also in mice in which MyD88 was 
deleted selectively in B cells, indicating that the observed increase in c-Myc-GFP can also 
occur by an indirect mechanism, mostly likely by induction following cognate interactions 
with Ag-specific Tfh cells. This indirect mechanism of promoting c-Myc protein expression 
in GC B cells could result from TLR9 signaling in other cell types, such as conventional 
dendritic cells or stromal cells such as follicular dendritic cells. Indeed, previous studies 
showed that TLR9 signaling in dendritic cells enhanced the number of Tfh cells following 
immunization with NP-CGG-CpG (13), possibly indicating increased availability of Tfh cell 
help for GC B cells. Interestingly, c-Myc protein levels were similar in WT and MyD88− 
GC B cells immunized with NP-CGG-CpG, whereas the c-Myc transcriptional program was 
stronger in the former mice. The lack of concordance between gene expression data in sorted 
GC B cells and c-Myc-GFP fluorescent reporter expression indicates that c-Myc–dependent 
transcription is not necessarily directly proportional to c-Myc protein levels in GC B cells. 
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Therefore, differences in the c-Myc–driven transcriptional signature could be orchestrated 
through c-Myc phosphorylation, binding partners, or chromatin accessibility (39, 40) 
programmed in activated B cells by dual BCR/TLR9 signaling that persists into the GC fate. 
This GC B cell–intrinsic enhancement of c-Myc transcriptional activity would perhaps 
enhance the effect of Tfh induction of c-Myc protein by making that c-Myc more active and 
driving higher levels of gene expression, accounting for the transcriptional profiling results.
The increased mTORC1 transcriptional signature identified by GSEA in GC B cells of mice 
immunized with NP-CGG-CpG was mirrored by increased phosphorylation of ribosomal 
protein S6, a downstream target of mTORC1. Although the MyD88− GC B cells showed a 
subtle defect in ribosomal protein S6 phosphorylation in vivo, the remaining observed 
response in these cells could have been due to CD40 stimulation resulting from cognate 
interactions with Tfh cells. In addition, we observed that ex vivo stimulation of GC B cells 
with a TLR9 ligand also induced an increase in phospho-S6 in the GC B cells, indicating 
that the NP-CGG-CpG likely also directly stimulated this pathway in WT GC B cells. 
Previous studies have demonstrated MyD88-mediated mTORC1 activation and binding in 
innate immune cells, and a similar process could occur in GC B cells (41).
Although TLR agonists can promote both T-independent and T-dependent Ab responses, the 
nature of the Ag and the presence of additional adjuvants can have a major impact on the 
contribution of TLR signaling to the response. Previous work has shown that the valency of 
the Ag and its propensity to cross-link the BCR dictate the impact of B cell–intrinsic 
MyD88-mediated signaling in shaping the GC response. Immunization with monovalent T-
dependent Ags (such as OVA) fused to CpG oligo shows no difference in GC B cell numbers 
or Ab titers between B-MyD88− and WT mice (7, 42), whereas B-MyD88− mice immunized 
with multivalent VLPs have a profound deficit in the GC response and Ab titers compared 
with WT mice (7, 14). Furthermore, addition of the lipid adjuvant DOTAP in conjunction 
with CpG oligo and NP-CGG, forming a multivalent particulate Ag, increased GC B cell 
and Tfh numbers as well as both high-affinity and low-affinity NP-specific Ab titers when 
compared with immunization with CpG oligo and NP-CGG in soluble form (15). However, 
when the same group performed experiments with CpG oligo and NP-CGG complexed with 
alum, they saw a decrease in high-affinity Ab titers against NP in WT mice compared with 
B-MyD88− mice (43). Moreover, the inclusion of alum to complex a large murine self-CpG 
DNA molecule with an amyloid conformed protein (chemically modified human serum 
albumin) also diminished total GC number and total anti–human serum albumin titers (28). 
These differences demonstrate that the exact conformation of the protein CpG oligo complex 
and other adjuvants, specifically alum, can profoundly affect the quality and quantity of the 
humoral response. The inclusion of alum and its inflammasome-mediated adjuvant activity 
in monocytes (44, 45) could be a complicating factor in these two experimental settings in 
which a decrease in the GC response was observed.
Although it is clear that TLR9 signaling in B cells can substantially promote the GC 
response (13–15), the exact timing of when TLR9-mediated MyD88 signaling influences the 
GC fate has not been well defined. This signaling event during early B cell activation could 
provide a selective advantage for initiating the GC or, alternatively, TLR9/MyD88 signaling 
event in GC cells could directly enhance their ongoing participation in the GC reaction. The 
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enhanced c-Myc and mTORC1 transcriptional programs seen in GC B cells on D14 are 
certainly consistent with the latter possibility, but these possibilities are not mutually 
exclusive. In our in vivo and ex vivo stimulation experiments, both naive and GC B cells 
responded directly to TLR9 stimulation by upregulating mTORC1 signaling and c-Myc 
protein expression. However, recent studies have demonstrated that MyD88 signaling during 
the initial activation of naive B cells in the response to nucleic acid-containing VLPs also 
plays a key role in activated B cell survival, proliferation, and Ag presentation to cognate T 
cells (23,46). Furthermore, deletion of Myd88 in activated B cells using Aicda-cre had a 
lesser effect than deletion of Myd88 with Mb1-cre prior to immunization, indicating that 
TLR/MyD88 signaling during the early phase of the responseis important in the response to 
CpG-containing VLPs (14). This observation bolsters the idea that dual BCR and TLR9 
signaling in naive B cells provides a selective advantage that is maintained days later in the 
GC response. Thus, the difference in numbers and percentage of GC B cells could be a result 
of differences in early activation, although our gene expression data indicate that there are 
persistent MyD88-signaling events that are maintained during the GC, at least through D14.
Both BCR and cosignaling through TLRs and anti-CD40 have been implicated in the 
metabolic reprogramming of activated B cells. Studies of early activation of B cells in vitro 
by BCR stimulation, TLR4 stimulation with LPS, or anti-CD40 + IL-4 stimulation to mimic 
helper T cell action have implicated increased glycolytic flux and increased oxidative 
phosphorylation as critical metabolic shifts during the initial activation of naive cells and for 
Ab production in vitro (47, 48). Interestingly, B cells that receive a BCR-mediated signal 
alone undergo toxic mitochondrial reprogramming, leading to apoptosis unless a secondary 
signal such as TLR stimulation or CD40-mediated signaling rescues this metabolic 
dysfunction (23). Thus, activation signals in naive B cells directly reprogram the 
mitochondria and necessitate cosignaling events for survival; however, the metabolic 
reprograming that occurs in GC B cells remains largely unknown. As discussed above, it is 
clear that Tfh cell help induces mTORC1 signaling and c-Myc expression (17–19), two 
mediators of metabolism and cell cycle regulation. Previous studies have implicated a 
synergy between BCR stimulation and anti-CD40–mediated Tfh cell help to induce 
mTORC1 (34), and our ex vivo stimulation data support the idea that cosignaling of BCR 
and TLR9/MyD88 induce mTORC1. In addition, we found that TLR9/MyD88 signaling in 
GC B cells enhanced expression of genes involved in oxidative phosphorylation and 
mitochondrial function (Fig. 1B, Supplemental Fig. 2, Table II).
This work adds to our basic understanding of the molecular pathways within the GC B cell 
by which TLR recognition promotes their response and has shown that this involves 
activation of mTORC1 and increased c-Myc transcriptional activity, two critical events also 
resulting from Ag presentation to Tfh cells. Such understanding may facilitate efforts to 
improve current vaccines or create new effective vaccines by rational approaches. The tight 
association of a CpG oligo to a protein Ag is in most circumstances sufficient to promote an 
increased humoral immunity and could serve as a strategy for vaccination, as can the use of 
VLPs containing nucleic acid ligands for TLR9 or TLR7. Such immunogens likely mimic to 
some degree the nature of virus particles and engage an evolutionarily derived mechanism to 
defend against viral infections. Using endosomal TLR adjuvants to shape the humoral 
response and provide more GC B cells could be beneficial in antiviral vaccine development.
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FDR false discovery rate
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FIGURE 1. mRNA-seq analysis of WT and B-MYD88− NP+ GC B cells shows increased c-Myc 
and mTORC1 gene expression signatures.
(A) Enumeration of GC B cell percentages and total cell numbers from draining lymph 
nodes of WT and B-MYD88− animals at D14 postimmunization. Representative of four 
independent experiments with at least three mice per group analyzed by a two-tailed Student 
t test, *p < 0.05, ***p < 0.0005. (B) Volcano plots comparing gene expression fold changes 
to p values for all genes expressed in at least one sample after DESeq2 analysis. Red dots in 
each panel indicate genes associated with the given metabolic/synthetic complex listed. (C) 
GSEA plots for hallmark gene sets for mTORC and c-Myc gene signatures enriched in WT 
transcriptional data. (D) GSEA plot from curated gene sets showing enrichment of 
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rapamycin- and serum-sensitive genes in WT samples. (E) GSEA plot from curated gene 
sets showing enrichment of c-Myc target genes in WT samples.
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FIGURE 2. Dual BCR/TLR9 signaling positively regulates c-Myc expression in naive and GC B 
cells.
(A) Overlay of representative histograms showing c-Myc-GFP expression in response to 
anti–IgM-CpG stimulation for 24 h of WT c-Myc-GFP and B-MYD88−c-Myc-GFP naive B 
cells. (B) Enumeration of percent GFP-positive and MFI of cells in (A) (shown is a single 
experiment representative of three independent experiments). (C) Overlay of representative 
histograms showing GFP fluorescence gating on live, singlet, CD19+, Fas+, IgDlo, and GL7+ 
GC cells of c-Myc-GFP+/+ mice immunized with NP-CGG-CpG or NP-CGG-Non D14 
postimmunization. (D) Enumeration of percent and number of GFP+ GC B cells from NP-
CGG-CpG- and NP-CGG-Non-immunized c-Myc-GFP+/+ mice (three combined 
experiments with at least three mice per group). (E) Enumeration of percent and number of 
GFP-positive cells from NP-CGG-CpG–immunized B-MYD88− and WT mice D14 
(representative experiment of three independent experiments). **p < 0.005, ****p < 0.0001. 
NS, p < 0.05 by one-way ANOVA and Holm–Sidak multiple comparison test.
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FIGURE 3. Dual BCR/TLR9 signaling positively regulates mTORC1 activity measured by 
ribosomal protein S6 phosphorylation in naiveand GC B cells.
(A) Overlay of representative histograms showing pS6(ser240/244) levels in response to 
anti–IgM-CpG for 24 h in WT and B-MYD88− naive B cells. (B) Enumeration of cell size 
by forward light scatter (FSC-A), percent pS6(ser240/244)+, and MFI of those cells gated 
positively for pS6(ser240/244) cells for WT and B-MYD88− naive B cells stimulated with 
anti–IgM-CpG and anti–IgM-Non. (C) Enumeration of cell size from D14 NP-CGG-CpG–
immunized B-MYD88− and WT non-GC and GC B cells (representative of four independent 
experiments). (D) Phospho-flow MFI of mTORC1 downstream target pS6(ser240/244) D14 
NP-CGG-CpG–immunized B-MYD88− and WT B cells normalized to mean of B-MYD88− 
GC MFI (data are combined from three experiments with at least three mice per group). (E) 
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Phospho-flow MFI of mTORC1 downstream target pS6(ser240/244) D14 NP-CGG-CpG-
and NP-CGG-Non-immunized mice normalized to mean MFI of NP-CGG-Non MFI 
(combined from two independent experiments with at least four mice per condition). *p < 
0.05, **p < 0.005, ****p < 0.0001. NS, p < 0.05 by one-way ANOVA and Holm–Sidak 
multiple comparison test.
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FIGURE 4. CpG stimulation of GC B cells ex vivo increases mTORC1 signaling to similar levels 
as anti-CD40 stimulation.
(A) Representative histograms comparing phospho-flow pS6(ser240/244) staining of 4 h ex 
vivo–stimulated naive and GC B cells isolated from i.p. NP-CGG alum–immunized mouse 
spleens at day 12 to D14 (three mice per experiment performed in three separate 
experiments). (B) Enumeration of experiments from (A), showing level of pS6(ser240/244) 
expression in naive and GC B cells from (A). (C) Overlays of c-Myc-GFP expression 
comparing no stimulation to the respective stimulation in naive and GC B cells after 4 h. (D) 
Enumeration of the relative c-Myc-GFP MFI increase normalized to no stimulation of the 
samples in (C) (representative of three independent experiments with at least three mice per 
experiment). *p < 0.05, ***p < 0.001, ****p < 0.0001. NS, p < 0.05 by one-way ANOVA 
and Tukey multiple comparison test.
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TABLE I.
B cell activation, class switch recombination, and cell fate gene expression
Gene Log2(KO/WT) Raw p Value FDR Value
Ighg2c −0.931278014 2.63 × 10−6 0.000742214
Fas 0.141497226 0.364147352 0.93944051
Cxcr4 0.364550474 0.115060865 0.6353624
Cd86 −0.155604203 0.313582804 0.90908692
Cd80 −0.247780304 0.381587211 0.93944051
Aicda −0.516289592 0.002956723 0.08882857
Prdm1 −1.091192869 0.003046472 0.08996182
Tir9 0.115035034 0.502823401 0.97633773
Myd88 −1.7156157 2.80 × 10−5 0.00412237
Bcl6 0.39066445 0.000556044 0.03277441
Bcl2 −1.081316005 0.000697559 0.03849734
Bold indicates FDR < 0.05 and an interpretation of significance. KO, B-MyD88−.
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